Performance of [68Ga]Ga-FAPI PET in Breast, Ovarian, and Cervical Cancers: A Systematic Review and Meta-Analysis

Asian Pacific Journal of Cancer Prevention, 2026

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.31557/apjcp.2026.27.4.1161
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

OBJECTIVE: This meta-analysis aims to evaluate the diagnostic efficacy of [68Ga]Ga-FAPI PET imaging in breast, ovarian, and cervical cancers by conducting a systematic review of the existing literature. METHODS: A systematic review of PubMed, Web of Science, Scopus, and Google Scholar databases, following by a meta-analysis of the included studies, was performed using a random-effects statistical model. RESULT: Ten eligible studies that described the effectiveness of [⁶⁸Ga]Ga-FAPI PET imaging in breast, ovarian, and cervical cancers were included in this review. The total number of participants was 253 females. Aggregated data from nine studies indicate a remarkably high diagnostic odds ratio (DOR) of 48.69 (95% CI: [16.94-139.96]) for detecting primary tumors, and a DOR of 207.50 (95% CI: [46.18-932.34]) from seven studies for detecting lymph node metastasis. [⁶⁸Ga]Ga-FAPI PET demonstrated high diagnostic accuracy in identifying both primary lesions and metastatic lymph nodes in breast, ovarian, and cervical cancers. CONCLUSION: [68Ga]Ga-FAPI PET imaging could function as a supplementary technique to [18F]F-FDG PET imaging modalities, offering a more comprehensive evaluation for cancer staging, assessment of treatment response, and guidance in radiation therapy planning.